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The splicing factor Prp18 is required for the second step of pre-
mRNA splicing. We have isolated and determined the crystal
structure of a large fragment of the Saccharomyces cerevisiae
Prp18 that lacks the N-terminal 79 amino acids. This fragment,
called Prp18D79, is fully active in yeast splicing in vitro and includes
the sequences of Prp18 that have been evolutionarily conserved.
The core structure of Prp18D79 is compact and globular, consisting
of five a-helices that adopt a novel fold that we have designated
the five-helix X-bundle. The structure suggests that one face of
Prp18 interacts with the splicing factor Slu7, whereas the more
evolutionarily conserved amino acids in Prp18 form the opposite
face. The most highly conserved region of Prp18, a nearly invariant
stretch of 19 aa, forms part of a loop between two a-helices and
may interact with the U5 small nuclear ribonucleoprotein particles.
The structure is consistent with a model in which Prp18 forms a
bridge between Slu7 and the U5 small nuclear ribonucleoprotein
particles.
Splicing of mRNA precursors takes place within the spliceo-some in two sequential transesterification reactions (re-
viewed in refs. 1–3). Five small nuclear ribonucleoprotein par-
ticles (snRNPs), U1, U2, U4, U5, and U6, participate in the
assembly of the spliceosome, but the two catalytic steps of
splicing appear to require only the U2, U5, and U6 snRNPs and
a large number of proteins. The U2 and U6 snRNAs, together
with the pre-mRNA, are thought to form the catalytic core of the
spliceosome, whereas the U5 snRNP interacts with exonic
sequences adjacent to both splice sites, possibly aligning the
exons during splicing.
We focus on the Saccharomyces cerevisiae splicing factor
Prp18, which is involved only in the second step of splicing (4, 5).
Five other yeast proteins—Prp8, Prp16, Prp17, Prp22, and
Slu7—are required for the second step of splicing (6–14) (re-
viewed in ref. 15). Prp18 is a 28-kD protein that lacks known
motifs that might suggest how it acts in splicing (16). Prp18 is
associated with the U5 snRNP (16, 17) and with the Slu7 protein
(18). Slu7 is involved in the selection of 39 splice sites and
interacts genetically with the U5 snRNA (13, 19, 20). Prp18 is not
absolutely required for splicing in vitro or in vivo; however, yeast
lacking Prp18 splice pre-mRNA extremely slowly and are tem-
perature sensitive (16). In vitro, the rate of the second step is
reduced nearly 100-fold by depletion of Prp18 (4).
The second step of splicing occurs in two stages. In the first
stage, which requires the Prp16 and Prp17 proteins, the hydro-
lysis of ATP fuels a conformational change in the spliceosome.
The transesterification reaction occurs in the second stage,
which requires Prp18, Prp22, Slu7, and perhaps Prp8, and is ATP
independent (4, 8–10, 19, 21–23). Three of the proteins needed
for the second stage—Prp18, Prp22, and Slu7—are dispensable
if the distance from the branch point to the 39 splice site is short
(10, 18, 20).
Human homologs of all six second-step proteins known in
S. cerevisiae have recently been identified and at least partly
characterized (24–31). The homologs appear to function very
similarly to their yeast counterparts, suggesting that the mech-
anism of the second step has been largely conserved.
Here we report the x-ray crystal structure of a large functional
fragment of Prp18 that includes the sequences of Prp18 that have
been evolutionarily conserved. The structure provides important
insights into the function of Prp18 in the second step.
Materials and Methods
Protein Purification and Crystallization. Limited proteolysis of pu-
rified Prp18 identifies a ’20-kDa fragment that resists further
digestion by Staphylococcus aureus endoprotinase Glu-C (V8
protease) (Calbiochem). N-terminal amino acid sequencing and
matrix-assisted laser desorption ionization mass spectrometry
showed that the N terminus of the proteolytic fragment was
Arg-80, and that the C-terminal end was intact. A recombinant
form of this fragment (Prp18D79) was produced in Escherichia
coli. Prp18D79 includes the initiating formyl-methionine at
position 79. E. coli strain BL21(DE3) carrying the expressing
plasmid was grown at 37°C until the OD (600 nm) reached 0.8,
induced with 0.4 mM isopropyl D-thiogalactoside, and grown at
23°C for 15–18 h.
Prp18D79 was purified by ammonium sulfate fractionation
hydrophobic (Phenyl-TSK, TosoHaas, Montgomeryville, PA)
and cation exchange (Mono S, Pharmacia) chromatography.
Concentrated Prp18D79 (5–10 mgyml) was crystallized by the
hanging-drop vapor diffusion method at 17°C. The best diffract-
ing crystals were grown with a well solution containing 100 mM
Mes pH 6.0, 10% glycerol, and 20% polyethylene glycol 8000.
Crystals used for x-ray diffraction typically had dimensions of
0.1 3 0.1 3 0.1 mm3.
Data Collection and Structure Determination. The crystal structure
was solved by the method of single isomorphous replacement
with anomalous scattering. A 2.2-Å resolution native data set
and a 2.7-Å Os derivative data set were collected by using a MAR
(MAR Research, Hamburg) imaging plate detector at 95 K and
l 5 1.09 Å. Both data sets were collected at beamline X26C at
the National Synchrotron Light Source, Brookhaven National
Laboratory (Upton, NY). Derivatized crystals were prepared by
soaking native crystals for 12 h in the crystallization-well solution
supplemented with 5 mM K2OsCl6. All raw diffraction data were
processed and scaled by using the HKL (32) software packages.
The PHASES software packages (33) were used for phasing and
for improving the quality of electron density map by solvent
flattening (34) and by phase recombination with a partial
polyalanine structure. Model building and refitting were per-
formed by using the graphics program O (35).
The structure was refined by using CNS (36). Crystallographic
R factor and free R (calculated with 10% of the full data set
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excluded from the refinement process) for the initial model were
43.9% and 43.7%, respectively, using the data in the resolution
range of 8.0–3.0 Å. These values dropped to 29.1% and 39.9%
after one cycle of torsion-angle simulated annealing carried out
with starting temperature at 10,000 K. All data were then
included in subsequent refinements with bulk solvent correction.
The stereochemistry of the refined model was assessed by the
PROCHECK program (37).
Assay of Prp18 and Prp18D79 Activities. Prp18-depleted yeast ex-
tract and hPrp18-depleted HeLa-cell nuclear extract (4, 24) were
supplemented with Prp18 or Prp18D79, the mixtures were incu-
bated on ice for 30 min, and splicing of actin pre-mRNA (yeast)
or b-globin pre-mRNA (human) was carried out for 15 min
(yeast) or 60 min (human) (38, 39).
Sequence Alignments. Alignments were done by using PILEUP and
GAP in GCG (Ver. 10.0). Accession numbers of the sequences are
S. cerevisiae L03536, Homo sapiens U51990, Arabidopsis thaliana
AC006550 (gene F10O3.3), Caenorhabditis elegans Z81074 (gene
F32B6.3), and Schizosaccharomyces pombe AL034490 (gene
SPCC126.14). The Drosophila melanogaster sequence was assem-
bled from 10 expressed sequence tag sequences.
Results and Discussion
Identification and Sequence Alignment of a Functional Domain of
Prp18. Full-length S. cerevisiae Prp18 did not crystallize in our
initial attempts. Limited proteolysis of Prp18 (251 amino acids)
yielded a stable fragment of ’20 kDa that appeared to represent
a single large domain of Prp18. Mass spectrometry and N-
terminal sequencing showed that this fragment was the C-
terminal two-thirds of Prp18 lacking the first 79 amino acids. A
recombinant form of the fragment, called Prp18D79, was pro-
duced in E. coli and used for the crystallographic studies. We
show below that Prp18D79 is fully functional in pre-mRNA
splicing in vitro.
An alignment of Prp18D79 with Prp18 proteins from five
diverse organisms is shown in Fig. 1. The human and yeast Prp18
proteins are known to be functional homologs (24); the other
Prp18s were identified by their sequence homology to these two
proteins. Similarity is highest in the C-terminal 80 amino acids,
and only in this region are the S. cerevisiae and S. pombe Prp18s
strongly homologous to those of the higher eukaryotes. Searches
of the recent databases confirm the previous report that the
Prp18s do not appear to be related to other proteins (24).
The Overall Structure of Prp18D79. The recombinant Prp18D79
crystallized with a C2221 symmetry and cell dimensions of a 5
49.94 Å, b 5 79.17 Å, and c 5 171.20 Å. There were two protein
molecules per asymmetric unit. The crystal structure was deter-
mined by using a single osmium derivative and refined to 2.15 Å
resolution (R factor 5 20.3%, and Rfree 5 25.2%; see Table 1 for
detailed statistics). The main chain electron density is continu-
Table 1. Statistics from the crystallographic analysis
Native Os derivative
Diffraction data
Resolution, Å 2.15 2.70
Observed reflections 188,477 69,049
Unique reflections 17,664 9,549
Completeness, % 93.2 99.1
Average Iys 16.9 10.8






Overall figure of merit 0.501
Refinement
Resolution range, Å 40.0–2.15
R factor,‡ Rfree 20.3% (25.2%)
Number of protein atoms 2,427
Number of water
molecules 332
Average B-factor 33.2 Å2
rms deviations




*Rmerge 5 (ï I2 ^I&ï y(^I&, where I is the measured intensity and ^I& is the
averaged intensity of multiple measurements of the same reflection. The
summation is over all observed reflections.
†Phasing power 5 rms (^FH&yE), where FH is the calculated structure factor of
the heavy atoms and E is the residual lack of closure.
‡R factor 5 (ïï FOï –ï FC ïï y(ï FO ï , where FO denotes the observed structure
factor amplitude and FC denotes the structure factor calculated from the
model.
Fig. 1. Alignment of sequences of five Prp18 proteins. S. cerevisiae Prp18D79 was aligned with the Prp18s of H. sapiens, D. melanogaster, A. thaliana, C. elegans,
and S. pombe. Positions at which four or more sequences are identical are shown red on blue; positions at which three sequences are identical are shown red
on cyan; and positions at which three or more sequences are similar are shown green on yellow. Similarities used are D’E, K’R, N’Q, A’G, C’S’T, V’L’I’M,
and F’Y’W. The positions of a-helices in the S. cerevisiae structure are indicated above the sequence. Loops 1 through 5, which precede helices 1 through 5,
are indicated by red lines; broken lines identify regions where the protein was disordered in the crystal. The A. thaliana Prp18 extends 32 aa beyond the end
shown here.








ous except for a 20-aa segment (Thr-198–Ala-217), which was
disordered in both of the molecules in the asymmetric unit and
could not be modeled reliably. The refined model has good
stereochemistry: the Ramachandran plot shows 94.4% of the
nonglycine nonproline residues are within the most favored
region, 4.8% in the additional allowed regions, and 0.7% in
generously allowed regions. The two molecules in the asymmet-
ric unit have essentially identical conformations. The two protein
molecules can be superimposed with a rms deviation of 0.55 Å
by using Ca atoms of well-ordered segments of the polypep-
tides (amino acids 84–197 and 218–246) for least-squares
superimposition.
The structure of Prp18D79 is shown in Fig. 2. The core
structure is formed by five a-helices, designated a1 through a5.
Helix a1 is connected to an additional short N-terminal helix, a0,
by a 20-residue loop (loop-1; f lanking loops are designated 1
through 5). The five helices, a1–a5, pack into a compact globular
structure. a1 and a2 are antiparallel, and they are packed at
approximately a 50° angle with respect to a3, a4, and a5 (Fig.
2A). The latter three helices are packed on one side of the a1-a2
plane, and they form a three-helix bundle (Fig. 2B).
Searches for structural similarity by using Prp18D79 as a query
against protein structure and folding databases resulted in no
significant matches. Visual inspection of representative protein
structures belonging to the five-helix folds confirmed that
Prp18D79 has a novel fold. By analogy with the classification of
four-helix bundle motifs (42), we term the Prp18D79 fold the
five-helix X-bundle. Helices a1 and a2 make direct contacts with
a3 and a5, whereas a4 is separated from a1 and a2 by a3 and
a5 (Fig. 2B). Helix a2 is bent in the middle because of the
presence of a conserved proline, Pro-145. The short N-terminal
helix a0 is located on the opposite side of the a1-a2 plane, and
it makes little contact with helices a1 and a2. The N terminus of
Prp18D79 points away from the core structure, suggesting that
the N-terminal 79 amino acids not included in this study should
not interfere with the folding of the C-terminal domain, namely
Prp18D79, in the full-length protein. The conformation of a0
observed in the structure might be stabilized by protein–protein
interactions in the crystal lattice, as it makes extensive interac-
tions with the same region of symmetry-related molecules.
Fig. 3. Activity of Prp18D79. (A) Prp18 or Prp18D79 was added to Prp18-
depleted yeast extract, and splicing of actin pre-mRNA was assayed. Lane 1
shows splicing in extract depleted with preimmune serum. Lane 2 shows
splicing in extract depleted by anti-Prp18 with no added Prp18. For the splicing
reactions displayed in lanes 3–8, the amount of Prp18 or Prp18D79 added is
shown at the top of each lane in femtomol per microliter of yeast extract. The
positions of lariat intermediate, lariat intron, pre-mRNA, mRNA, and exon1
are shown at the left of both A and B. (B) Prp18, Prp18D79, or hPrp18 was
added to hPrp18-depleted HeLa-cell nuclear extract, and splicing of b-globin
pre-mRNA was assayed. Lane 1 shows splicing in hPrp18-depleted extract
alone. For lanes 2–12, the amount of Prp18, Prp18D79, or hPrp18 added is
shown at the top in femtomol per microliter of nuclear extract.
Fig. 2. Overall structure of Prp18D79. (A) Front view of the Prp18D79 structure shown in a ribbon representation. The protein core has a five-helix X bundle
structure. The N and C termini and all helices are labeled. The dotted line represents the disordered segment of loop-5. (B) Another view of the Prp18D79 structure
(rotated 210° with respect to a vertical axis) showing that helices a3, a4, and a5 are antiparallel and located on the same side of the a1–a2 plane. Loop-5
connecting helices a4 and a5 are exposed. The figure is produced with MOLSCRIPT (40) and RASTER3D (41).
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Although there are two Prp18D79 molecules per asymmetric
unit, only the monomeric form was detected in solution using
both dynamic-laser scattering and gel filtration (data not shown).
In the Prp18D79 crystals, the contact area between the two
molecules in the asymmetric unit is rather small; a total area of
792 Å2 is buried by the protein contact, about half that seen for
specific and stable protein–protein interactions (43). The data
suggest that Prp18D79 is a monomer in solution and that the
dimeric interaction in the asymmetric unit is most likely a result
of crystallization.
Activity of Prp18D79 in pre-mRNA Splicing. The activity of Prp18D79
was tested by complementation of Prp18-depleted extracts.
Yeast extract depleted of Prp18 is defective in second-step
splicing, and addition of recombinant Prp18 to the depleted
extract restores splicing (Fig. 3A, lanes 2–5) (4). Recombinant
Prp18D79 also restored full splicing activity to Prp18-depleted
yeast extracts (Fig. 3A, lanes 6–8). The activities of Prp18 and
Prp18D79 were very similar at all concentrations tested.
Prp18D79 was also assayed in hPrp18-depleted HeLa-cell nu-
clear extracts (24). Both full-length yeast Prp18 and Prp18D79
were active in the complementation assay (Fig. 3B), and their
activities were quite similar. Prp18D79, therefore, is an evolu-
tionarily conserved functional domain of Prp18. The N-terminal
domain of Prp18 does not appear to play a role in splicing in vitro,
despite some weak conservation of amino acid sequences near
the N terminus (not shown) (24).
Interaction Between Prp18 and Slu7. Prp18 interacts with Slu7
genetically and physically (8, 13, 18). The crystal structure shows
how Slu7 can interact with one positively charged face of Prp18.
The region of Slu7 required for interacting with Prp18 has been
Fig. 4. Surface characteristics of the Prp18D79 structure. (A) Electrostatic potential on the protein surface, viewed from a similar direction as in Fig. 2A. Positive
charges are shown in blue, negative charges in red. Charged residues are labeled by their standard single-letter code followed by the residue number in the
sequence. The green circle identifies the proposed Slu7-interacting area. His-118 on a2 is also labeled, although histidines are not included in calculating the
electric potential on the surface (charges were assigned only to Lys and Arg, Asp and Glu). The surface was calculated by using a probe radius of 1.4 Å, and the
potential is displayed at a 215 kBT to 1 15 kBT scale, where kB is the Boltzmann constant. The region on the right side concentrated with positively charged
residues is the putative Slu7-binding region. (B) Rear view (the protein is rotated 180° with respect to a vertical axis). The yellow arrowheaded ribbon indicates
schematically the location of the disordered segment in loop-5. The direction of the arrowhead indicates the amino to carboxyl direction of the segment. The
figures were generated with the program GRASP (44). (C) Corey–Pauling–Koltun representation of the Prp18D79 structure viewed from the same direction as in
A. Residues implicated in interacting with Slu7 by the two-hybrid method are colored red; conserved residues (S. cerevisiae residues shared by three or more other
species as shown in Fig. 1) are colored blue; conserved residues that lie within the Slu7 interacting region are colored magenta, and all others are colored cyan.
(D) Rear view. Most invariant residues are located on this side of the surface (the disordered segment of loop-5 is not shown, but it is also expected to be located
on this side of the protein). These residues are not involved in interacting with Slu7.








mapped to a 25-aa segment (amino acids 200–224) by the
two-hybrid method (18). This segment is rich in negatively
charged residues (a total of 12 charged residues, 9 negative and
3 positive). The portion of Prp18 needed for interaction with
Slu7 has been mapped to a fragment encompassing amino acids
98 to 179, also by the two-hybrid assay (D.S.H., T. Niccoli, B.
Schwer, and A. R. Krainer, unpublished data). This region
encompasses a small part of loop-1, and a-helices 1, 2, and 3, but
does not include the most conserved part of Prp18 (Fig. 1). The
charge distribution on the protein surface is shown in Fig. 4 A
and B. a-Helices a1 and a2 (amino acids 106–126 and 133–151)
are contiguous and form a positively charged surface, consistent
with a role in interacting with Slu7 (Fig. 4A). Helix a3 (amino
acids 157–171) is almost entirely buried inside Prp18 and does
not appear to contact Slu7 directly. Nine positively charged
residues are all located on the same face of Prp18 (Fig. 4A).
Within the mapped interaction region, His-118 and Lys-125 on
a1, Lys-140 and Lys-141, Arg-151, and Arg-152 on a2 are
positively charged. In addition, Arg-80 on a0, Lys-89 on loop-1,
and Arg-225 on a5 are located on the same side of the protein
surface (Fig. 4A). These charged residues are only partly con-
served. However, by superimposing the sequences of other Prp18
proteins on the yeast Prp18 structure, we find that all of the
Prp18s except that of S. pombe have a positively charged surface
formed by helices a1 and a2 (not shown). Interestingly, the
region of Slu7 involved in interacting with Prp18 is also not well
conserved in other organisms (including humans, C. elegans, and
A. thaliana) except for its negatively charged nature (data not
shown; ref. 29). It is worth noting that the S. pombe Slu7 differs
significantly in the putative Prp18-binding region, which may
account for the corresponding differences in the S. pombe Prp18.
The sequences and structures strongly suggest that charge
complementarity is an important part of the Prp18–Slu7 inter-
action. However, one should bear in mind that the two-hybrid
studies of the interaction of Slu7 with Prp18 both used deletions
of the proteins; the results, therefore, identify a minimal region
needed for interaction, but do not preclude other contacts
between the proteins.
The Conserved Region of Prp18. The Prp18 proteins are most
closely related in their C-terminal 80 amino acids. (Fig. 1).
Especially striking is the nearly invariant block of amino acids
from 188 through 203 (S. cerevisiae numbering). Even S. pombe
Prp18, the most distantly related of the Prp18s, is highly con-
served in this region. There do not appear to be any other
proteins that have this sequence, which appears to be the
‘‘signature’’ of Prp18s.
The highly conserved residues in yeast Prp18 are distributed
in a region encompassing the C-terminal end of a4, loop-5, and
a5. This region occupies a large area on the protein surface, and
it is spatially distinct from the surface that likely interacts with
Slu7. In Fig. 4 C and D, the conserved residues are highlighted
in blue, the residues implicated in Slu7 interaction in red, and
residues that are both conserved and Slu7-interacting in ma-
genta. The surface formed by these conserved residues is on the
opposite face from the putative Slu7-binding area (Fig. 4D). This
conserved surface can be divided into two parts, one of which is
rigid and the other, f lexible. Exposed residues located on helices
a4 and a5 form the rigid part. This part of the surface is stable
because a4 and a5 are rigidly embedded in the structure as they
are part of the core of the protein. The second, f lexible part
consists of the 36-aa loop-5, which contains the most conserved
residues in Prp18. Part of loop-5, residues 198–217, is disordered
and appears to be entirely exposed to the solvent. The ordered
portions of loop-5 are also located on the protein surface. The
N- and C-terminal portions of loop-5 are stabilized by interaction
with residues located on helices a3, a4 and the C-terminal
portion of loop-1. In view of its accessibility and high degree of
conservation, loop-5 is likely to function in protein–protein
interactions.
The conserved surface of Prp18 is likely to be the site for
interaction of Prp18 with other components of the spliceosome.
Both the conservation and the flexibility of the conserved
surface point to this conclusion; regions of proteins that are
involved in ligand binding are often flexible in their unbound
form. The conservation of this surface contrasts with the evo-
lutionary divergence of sequences in the Prp18–Slu7 interaction
region. Several causes could be responsible for restricting
changes in this region: (i) The conserved sequences in Prp18 may
interact with more than one factor; (ii) Prp18 could interact with
a factor that is highly conserved; (iii) the conserved amino acids
may perform a specific function during the second step.
The functional results imply that the conserved portion of
Prp18 may be strictly required for activity. Yeast Prp18 can
restore splicing activity to HeLa cell nuclear extracts that have
been depleted of hPrp18 (24). Yeast Prp18 has much lower
affinity for the human spliceosome than does hPrp18 (Fig. 3).
However, when sufficient yeast Prp18 is present to drive the
binding of the human spliceosome to yeast Prp18, yeast Prp18 is
only a few-fold less active in splicing. Yeast Prp18 likely fails to
make specific contacts with the human spliceosome; for exam-
ple, the portion of Prp18 that interacts with Slu7 is not con-
served. The activity of yeast Prp18 in human splicing is almost
certainly because of the highly conserved C-terminal part of the
protein, strongly arguing that this portion of Prp18 is functionally
indispensable.
Interaction Between Prp18 and the U5 snRNP. Yeast Prp18 is
associated with the U5 snRNP, and we surmise that the con-
served surface of Prp18 interacts with the U5 snRNP. Immu-
noprecipitation experiments and, more recently, purification of
intact U4yU6zU5 snRNP particles both show that Prp18 is part
of the U5 snRNP, although Prp18 binding to U5 is relatively
weak, and Prp18 dissociates from the snRNP at moderate salt
concentrations (16, 17). Association of Prp18 with the U5 snRNP
may be transient; hPrp18 is not stably bound to the U4yU6zU5
snRNP and is stably associated with spliceosomes only during the
second step (24). Yeast PRP18 interacts genetically with loop-I
of U5 snRNA (13). Loop-I is highly conserved and interacts with
exonic sequences at the 59 and 39 splice sites and is specifically
required for the second step of splicing in yeast (45, 46). The
biochemical and genetic results show that the U5 snRNP and
Prp18 interact, and it seems likely to us that the critical con-
served interactions of Prp18 are with the U5 snRNP. The
structural data do not suggest how Prp18 interacts with the U5
snRNP.
Fig. 5. A schematic drawing showing the proposed model of the Prp18
function in the second step of splicing. Pre-mRNA is shown in purple; exons 1
and 2 are indicated. Prp18 is shown in red and in contact with both Slu7 (green)
and U5 snRNP (orange); the latter two contact the 39 splice site directly. U2
(cyan) and U6 (black) snRNPs are shown to indicate their involvement in the
second step splicing reaction.
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A Model of Prp18 Action. A model of how Prp18 could function in
the second step can be proposed based on the crystal structure
and the above arguments. The crystal structure reveals that
Prp18 has distinct interaction sites, suggesting that Prp18 can
interact with the U5 snRNP and Slu7 simultaneously. Both the
U5 snRNP and Slu7 interact with the 39 splice site (7, 23, 45, 47);
no stable association of Slu7 with U5 snRNP has been reported,
although they do interact genetically (13). Prp18 may function as
a bridge between Slu7 and U5 snRNP, making their association
more stable at the 39 splice site. A schematic drawing of the
model is shown in Fig. 5.
The proposed model can account for many of the observed
properties of Prp18. Schwer and coworkers have shown that both
Prp18 and Slu7 are needed only if the distance between the 39
splice site and the branch point is more than 12 nt (18, 20). When
the branch point to 39 splice site distance is short, U5 can bind
to the 39 splice site sufficiently tightly to allow splicing. When the
distance is large, Slu7 and Prp18 are required to stabilize the
binding of U5 to the 39 splice site. Prp18, acting as a bridge
between U5 and Slu7, stabilizes the binding of the U5 snRNP to
the 39 splice site. If Slu7 is present at high levels, then it could
stabilize the binding of the U5 snRNP itself if it makes some
contact with the U5 snRNP. This model, in which Prp18
stabilizes a conformation of the spliceosome, is consistent with
the temperature sensitivity of PRP18-knockout strains.
We have determined the crystal structure of a fully functional
portion of yeast Prp18. This domain is conserved from yeast to
human, and the structure will be the basis for understanding the
function of Prp18 in pre-mRNA splicing. We propose that Prp18
functions to stabilize the interaction between Slu7 and the U5
snRNP at the 39 splice site during the second step of splicing.
Only a limited amount of structural information on proteins
involved in pre-mRNA splicing is currently available. To our
knowledge, the structure of Prp18D79 that we report is the first
of a splicing factor involved specifically in the catalytic steps of
splicing. Further structural information on second-step proteins
will allow more precise placement of Prp18 in the spliceosome.
This type of structural information will be vital for understand-
ing the mechanism of pre-mRNA splicing.
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